{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:19:03Z","timestamp":1761733143655,"version":"build-2065373602"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alexion Pharma GK"},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ravulizumab, a long-acting anti-C5 antibody, was approved for atypical hemolytic uremic syndrome (aHUS) in September 2020 in Japan. Post-marketing surveillance was mandated by local regulatory authorities to evaluate the effectiveness and safety of ravulizumab in patients with aHUS in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with aHUS who switched from eculizumab to ravulizumab and received at least one dose of ravulizumab between September 2020 and December 2021 were enrolled. The effectiveness was evaluated by thrombotic microangiopathy (TMA) event-free status, defined as no sign of TMA recurrence and no initiation of plasma therapy\/dialysis during ravulizumab treatment. The safety of ravulizumab was evaluated by summarizing the incidence of adverse events (AEs) and serious AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 33 patients (19 children and 14 adults). The median (range) duration of eculizumab treatment before the switch was 1233 (113\u20133240) days, and the duration of ravulizumab treatment was 351 (127\u2013365) days. During ravulizumab treatment, TMA event-free status was achieved in 97.0% (32\/33) of patients. The platelet count, lactate dehydrogenase levels, and serum creatinine levels remained stable during ravulizumab treatment. Twenty-nine AEs were reported in 13 patients, including nine serious AEs in seven patients. No meningococcal infections or deaths occurred during ravulizumab treatment. One patient discontinued treatment and died 478\u00a0days later from an unknown cause.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study confirmed the effectiveness and safety of ravulizumab in Japanese patients with aHUS after switching from eculizumab in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-025-02689-6","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T02:38:39Z","timestamp":1749868719000},"page":"1608-1617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance"],"prefix":"10.1007","volume":"29","author":[{"given":"Shuichi","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-632X","authenticated-orcid":false,"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2689_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","volume":"2016","author":"V Afshar-Kharghan","year":"2016","unstructured":"Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematol Am Soc Hematol Educ Program. 2016;2016:217\u201325.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2689_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41100-016-0088-1","volume":"3","author":"Y Yoshida","year":"2017","unstructured":"Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther. 2017;3:5.","journal-title":"Ren Replace Ther"},{"key":"2689_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1055\/s-0034-1376153","volume":"40","author":"M Riedl","year":"2014","unstructured":"Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014;40:444\u201364.","journal-title":"Semin Thromb Hemost"},{"key":"2689_CR4","unstructured":"Research Group on Blood Coagulation Disorders. [Clinical guide for atypical hemolytic uremic syndrome 2023]. 2023. https:\/\/jsn.or.jp\/academicinfo\/report\/aHUS_GL2023.pdf. Accessed 11 Sep 2024. [In Japanese]."},{"key":"2689_CR5","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2689_CR6","unstructured":"PMDA Soliris\u00ae package insert. https:\/\/www.pmda.go.jp\/drugs\/2019\/P20191205001\/870056000_22200AMX00316_B100_1.pdf. Accessed 14 Apr 2025. [In Japanese]."},{"key":"2689_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20:125.","journal-title":"BMC Nephrol"},{"key":"2689_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"},{"key":"2689_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373.","journal-title":"Kidney Int"},{"key":"2689_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701\u201311.","journal-title":"Kidney Int"},{"key":"2689_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68:84\u201393.","journal-title":"Am J Kidney Dis"},{"key":"2689_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","volume":"23","author":"S Ito","year":"2019","unstructured":"Ito S, Hidaka Y, Inoue N, et al. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23:112\u201321.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","volume":"23","author":"H Kato","year":"2019","unstructured":"Kato H, Miyakawa Y, Hidaka Y, et al. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23:65\u201375.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfac150","volume":"38","author":"S Ito","year":"2023","unstructured":"Ito S, Hataya H, Ashida A, et al. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrol Dial Transplant. 2023;38:414\u201324.","journal-title":"Nephrol Dial Transplant"},{"key":"2689_CR15","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s40620-024-01921-y","volume":"37","author":"S Maruyama","year":"2024","unstructured":"Maruyama S, Ikeda Y, Kaname S, et al. Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance. J Nephrol. 2024;37:2181\u201390.","journal-title":"J Nephrol"},{"key":"2689_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13:e0195909.","journal-title":"PLoS ONE"},{"key":"2689_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97:1287\u201396.","journal-title":"Kidney Int"},{"key":"2689_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","volume":"100","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2021;100:225\u201337 (Erratum in: Kidney Int. 2023;104:205).","journal-title":"Kidney Int."},{"key":"2689_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","volume":"36","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36:889\u201398.","journal-title":"Pediatr Nephrol"},{"key":"2689_CR20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","volume":"6","author":"T Barbour","year":"2021","unstructured":"Barbour T, Scully M, Ariceta G, et al. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6:1603\u201313.","journal-title":"Kidney Int Rep"},{"key":"2689_CR21","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ekir.2024.06.020","volume":"9","author":"F Schaefer","year":"2024","unstructured":"Schaefer F, Al-Dakkak I, Anokhna K, et al. Global atypical hemolytic uremic syndrome registry analysis of patients switching to ravulizumab from eculizumab. Kidney Int Rep. 2024;9:2648\u201356.","journal-title":"Kidney Int Rep."},{"key":"2689_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","volume":"25","author":"K Sch\u00f6nfelder","year":"2024","unstructured":"Sch\u00f6nfelder K, K\u00fchne L, Schulte-Kemna L, et al. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS\u2013 real-world data. BMC Nephrol. 2024;25:202.","journal-title":"BMC Nephrol"},{"key":"2689_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","volume":"7","author":"AA Acosta-Medina","year":"2023","unstructured":"Acosta-Medina AA, Moyer AM, Go RS, et al. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023;7:340\u201350.","journal-title":"Blood Adv"},{"key":"2689_CR24","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0036","volume":"12","author":"TJ Mauch","year":"2023","unstructured":"Mauch TJ, Chladek MR, Cataland S, et al. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023;12:e230036.","journal-title":"J Comp Eff Res"},{"key":"2689_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10157-013-0911-8","volume":"18","author":"T Sawai","year":"2014","unstructured":"Sawai T, Nangaku M, Ashida A, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18:4\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10157-017-1524-4","volume":"22","author":"H Kato","year":"2018","unstructured":"Kato H, Nangaku M, Okada H, et al. Controversies of the classification of TMA and the terminology of aHUS. Clin Exp Nephrol. 2018;22:979\u201380.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR28","unstructured":"Ravulizumab package insert. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070019. Accessed 11 Sep 2024. [In Japanese]."},{"key":"2689_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"2689_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2689_CR31","doi-asserted-by":"publisher","first-page":"1264310","DOI":"10.3389\/fmed.2023.1264310","volume":"10","author":"A \u00c1vila","year":"2023","unstructured":"\u00c1vila A, Cao M, Espinosa M, et al. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med (Lausanne). 2023;10:1264310.","journal-title":"Front Med (Lausanne)"},{"key":"2689_CR32","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137:2438\u201349.","journal-title":"Blood"},{"key":"2689_CR33","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","volume":"14","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Fakhouri F, Sartz L, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14:2075\u201384.","journal-title":"Clin Kidney J"},{"key":"2689_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91:539\u201351.","journal-title":"Kidney Int"},{"key":"2689_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100683","volume":"5","author":"Y Wang","year":"2023","unstructured":"Wang Y, Al-Dakkak I, Garlo K, et al. Atypical hemolytic uremic syndrome treated with ravulizumab or eculizumab: a claims-based evaluation of health care resource utilization and clinical outcomes in the United States. Kidney Med. 2023;5:100683.","journal-title":"Kidney Med"},{"key":"2689_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"JI Nishimura","year":"2023","unstructured":"Nishimura JI, Kawaguchi T, Ito S, et al. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118:419\u201331.","journal-title":"Int J Hematol"},{"key":"2689_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12185-025-03921-5","volume":"121","author":"JI Nishimura","year":"2025","unstructured":"Nishimura JI, Kawaguchi T, Ito S, et al. Correction: Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2025;121:560\u20132.","journal-title":"Int J Hematol"},{"key":"2689_CR38","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2019-122421","volume":"134","author":"S Cataland","year":"2019","unstructured":"Cataland S, Ariceta G, Chen P, et al. Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019;134:1099.","journal-title":"Blood"},{"key":"2689_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112944","volume":"490","author":"MAV Willrich","year":"2021","unstructured":"Willrich MAV, Ladwig PM, Martinez MA, et al. Monitoring ravulizumab effect on complement assays. J Immunol Methods. 2021;490:112944.","journal-title":"J Immunol Methods"},{"key":"2689_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson R, Lindner S, Bordereau P, et al. Standardisation of the factor H autoantibody assay. Immunobiology. 2014;219:9\u201316.","journal-title":"Immunobiology"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02689-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:33:46Z","timestamp":1761708826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02689-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akihiko Shimono and Masaki Okuda are employees of Alexion Pharma GK, the study sponsor. Hirofumi Teranishi was an employee of Alexion Pharma GK at the time of the study. Shuichi Ito, Hiroshi Hataya, Masanori Matsumoto, Yoshitaka Miyakawa, and Shoichi Maruyama report payment for lectures and advisory board participation from Alexion Pharma GK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval by an institutional review board is not mandatory for PMS. Informed consent from individual patients\/caregivers was not required for inclusion in this observational study mandated by the Japanese authorities. However, patients who provided consent for the use of data for publication were included in this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PMS was mandated by the Japanese government as part of the regulatory approval of ravulizumab for aHUS in Japan. PMS was conducted in accordance with Good Post-Marketing Study Practice (Ministry of Health, Labour and Welfare, Ministerial Ordinance No. 171 of 2004) to evaluate the safety and effectiveness of ravulizumab in clinical practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Because this PMS was mandated as a condition of ravulizumab approval and was conducted in accordance with the Japanese Good Post-Marketing Study Practice requirements (Ministry of Health, Labour and Welfare, Ministerial Ordinance No. 171 of 2004), informed consent from individual patients\/caregivers was not required. However, informed consent was required for the use of data for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}